The prescription pattern of first-line antihypertensives among family medicine trainees in Hong Kong - Part 2: In the presence of diabetes

Hong Kong Practitioner

Volumn 27, Issue 3, 2005, Pages 83-92

  Wong, Martin C S ^a,c   Chung, Roger Y ^b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c Lek Yuen Health Centre   (Hong Kong)

Author keywords

Antihypertensives; Diabetes; First line; Prescription

Indexed keywords

BISOPROLOL FUMARATE PLUS HYDROCHLOROTHIAZIDE; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN HEXETIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; LODOZ;

ACADEMIC ACHIEVEMENT; AGING; ARTICLE; COMPETENCE; DIABETIC HYPERTENSION; DRUG CHOICE; DRUG INDUCED DISEASE; EXPERIENCE; FAMILY MEDICINE; FEMALE; HEALTH SURVEY; HONG KONG; HUMAN; INTERVIEW; MALE; MEDICAL DECISION MAKING; MEDICAL EDUCATION; MEDICAL PRACTICE; PRESCRIPTION; PRIMARY HEALTH CARE; PROFESSIONAL PRACTICE; SEX DIFFERENCE; STAFF TRAINING;

EID: 20044387110     PISSN: 10273948     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Murtagh J. General Practice, second edition. McGraw-Hill Book Company Australia Pty Limited. 1999;Table 111.6:1082.
2. Michigan Quality Improvement Consortium. Medical management of adults with essential hypertension. Southfield (MI): Michigan Quality Improvement Consortium; 2003 Aug. 1 p.
3. Kumar P, Clark M. Clinical Medicine: A Textbook for Medical Students and Doctors. Third edition 1994;Table 11.38:622.
4. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:1456-1462.
5. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiocadcular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869.
6. Wright JM. Choosing a first-line drug in the management of elevated blood pressure: What is the evidence? 3: Angiotensin-converting- enzyme-inhibitors. CMAJ 2000;163:293-296.
7. Kasiske BL, Kalil RS, Ma JZ, et al. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 1993;118:129-138.
8. Giatras I, Lau J, Levey AS. Effect of angiotensin-converting enzyme inhibitors on the progression of non-diabetic renal disease: a meta-analysis of randomised trials. Ann Intern Med 1997;127:337-345.
9. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. US Department of Health and Human Services, NIH Publication No. 03-5233, May, 2003:15.
10. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-860.
11. American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care 2003;26 (suppl 1): S80-S82.
12. National Kidney Foundation Guideline. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis 2002;39 (suppl 2):S1-S246.
13. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998;317:713-720.
14. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-2997.
15. Wu AY, Kong NC, de Leon FA, et al. for the MAPS Investigators. An alarmingly high prevalence of diabetic nephropathy in Asian type 2 diabetic patients: the MicroAlbuminuria Prevalence (MAP) Study. Diabetologia 2004 Dec 23; [Epub ahead of print].
16. Filler. Diuretics should be the first line treatment for hypertension. BMJ 2003; 327 (30 August).
17. Lau GS, Chan JC, Chu PL, et al. Use of antidiabetic and antihypertensive drugs in hospital and outpatient settings in Hong Kong. Ann Pharmacother 1996;30:232-237.
18. Wong MCS, Chung RY. The prescription pattern of antihypertensives among Family medicine trainees in Hong Kong Part 1: in the absence of concomitant cardiovascular risk factors. HK Pract 2004;26:420-429 see appendix for full questionnaire.
19. Annual Report 2002-2003, pp. 18-23. The Hong Kong College of Family Physicians. Submitted by the Honorary Secretary at the HKCFP Annual General Meeting on 12th December, 2003 (Under Board of Vocational Training and Standards, p. 17-18, "Higher trainees" include those from (a). "Output Congratulations", (b). Certified completion of 4-year Basic Training; (c). Certified completion of 2-year Higher training, and (d). Appendix A: Trainees in Higher Vocational Training in Family Medicine 2002/2003)
20. World Health Organization / International Society of Hypertension Guidelines. J Hypertens 1999;17:151-183.
21. Chan NN, Kong APS,Chan JCN. New-onset diabetes and antihypertensive drugs: implications for renin-angiotensin system blockade. HK Pract 2004; 26:515-519.
22. Julius S, Kjeldsen SE, Weber M. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet 2004;362:2022-2031.
23. Cheung BMY. Sartans for hypertension - implications of the Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial. HKMJ 2004; 10: 359.
24. Posch PJ. Diuretics and diabetes. (Rapid responses to "Diuretics should be the first line treatment for hypertension. BMJ 2003; 327 (30 August)) BMJ 2003;4 Sept.
25. Wright JM, Lee C, Chambers GK. Systematic review of antihypertensive therapies: Does the evidence assist in choosing a first-line agent? CMAJ 1999;161:25-32.
26. Wright JM. Choosing a first-line drug in the management of elevated blood pressure. What is the evidence? 1: Thiazide diuretics. CMAJ 2000; 163: 57-60.
27. Wright JM. Choosing a first-line drug in the management of elevated blood pressure. What is the evidence? 2: β-blockers. CMAJ 2000;163:188-192.
28. Tam TKW, Cheng LPK, Lau DMW, et al. The prevalence of microalbuminuria among patients with type II diabetes mellitus in a primary care setting: cross-sectional study. HKMJ 2004;10:5.
29. Williams B. Drug treatment of hypertension (Editorials) BMJ 2003;326:61-62.
30. Sequeira RP, Jassim AK, Damanhori, et al. Physician gender and antihypertensive prescription pattern in primary care. J Eval Clin Pract 2003; 9:409-415.